



Company Profile

2020

Yes, We Care



Message from the Chairman of the Board of Directors

On behalf of the Board of Directors of EIPICO, I would like to present to you our company profile which I trust you will find as a reliable, useful and valuable source of information.

Our motto, “Yes, We Care”, reflects our assiduous effort and ongoing striving to assist healthcare systems, whether domestically or internationally, by providing high quality pharmaceutical products at reasonable prices.

EIPICO was the leading pharmaceutical company in Egypt to apply Good Manufacturing Practice (GMP), the system for ensuring that products are consistently produced and controlled according to quality standards.



Message from the Chairman of the Board of Directors

EIPICO is, currently, one of the leading Egyptian pharmaceutical companies, in terms of production and sales, in the local market. It is the leading company in pharmaceutical exports, capturing a 21% share of the total Egyptian pharmaceutical export market.

Our product portfolio comprises more than 400 products, covering more 24 therapeutic classes, including: antibiotics, antivirals, anaesthetics, as well as, ophthalmic, cardiovascular, gastrointestinal, genitourinary and respiratory drugs and many more.

Through generating innovative entrepreneurial ideas, meticulous planning, and with the support of hardworking, enthusiastic, diligent, high-performance teams, working in tandem, and committed to their duties, we shall continue to fulfill our mission of expanding our production of high quality products, to satisfy the needs of the medical community.



Message from the Chairman of the Board of Directors

EIPICO will continue to improve its efficiency in every aspect and will continuously endeavor for evolution, saving no effort to meet the current and future expectations of the healthcare systems and to contribute to the healthcare development of our country.

Finally, I would like to express my deepest thanks to our shareholders and to the medical and pharmaceutical professionals for their trust, our partners and suppliers for their support and our employees for their relentless efforts to maintain our position as a leading pharmaceutical company.

Chief Executive Officer



Our Vision



To be One of the World's Leading
Pharmaceutical Companies



Our Mission

Providing Highest Quality Medicines
at affordable prices for Patients.

Providing our Investors with a Superior
Rate of Return.

Maintaining an Inspiring Work
Environment for our Employees.



Our Core Values

Genuine Care

We genuinely care for patients everywhere. We have been able to build trust in our products and we are committed to exerting all efforts to keep the healthcare professionals' and patients' continuous trust.

Integrity

We believe that doing our jobs with integrity and conscientiousness is the sole key to great achievements.

Fairness

We work on the balance of justice, equity and rights distribution, as we believe that these principles will guarantee that our staff will save no efforts to achieve our business goals.

Product Quality

We work on the quality of our products to ensure their efficacy and safety are up to the highest standards. Highest quality besides respect for the environment are among our priorities.

Teamwork

We build high-performance teams working harmoniously together to achieve assigned missions with the best possible results.

Empowerment

EIPICO gives the opportunity and confidence to its staff through authorization and delegation to assume responsibilities and contribute to the overall company's success.

Innovation

EIPICO has a climate that helps creativity and innovation which eventually leads to the continuous development of our business.

High Performance

Our performance is the practical way to express our commitment to the principles and duties of work. We always aim at improving our performance to reach the highest levels.

Loyalty

The individual affiliation of EIPICO stems from the company's social contributions to the individual and gives the members of EIPICO pride and belonging to their work in the company.



Our Responsibilities

EIPICO is committed to its social responsibility and is currently contributing to the **"100 Million Healthy Lives"** National Campaign aiming at elimination of hepatitis C virus (HCV).

EIPICO donated 15,000 packs of Episovir 400 mg Tablets to the Ministry of Health in order to support all national efforts and achieve Egypt's dream.

Egypt to be Free from Virus C by 2020



EIPICO ... Yes We Care

EIPICO was established in Tenth of Ramadan City in 1980, with a capital of L.E. 7 Million, currently raised to L.E. 1500 Million, as an Egyptian public shareholder company operating according to the Investment Law (No. 43/1974 modified by Law No. 32/1977).

EIPICO started production in 1985 as the Leading Company in Egypt and the Middle East and North Africa (MENA) Region, to produce pharmaceutical products according to Good Manufacturing Practice (G.M.P.) regulations, with the aim of providing local and international markets with high quality products at affordable prices.

EIPICO has 2 Plants built over a surface area of 120 thousand square meters, which fully operate in compliance with cGMP regulations, to assure the safety and efficacy of the pharmaceutical products.



EIPICO ... Yes We Care


EIPICO is unique with its 9 sterile areas, which are the Largest and Most Advanced, in Egypt and in the MENA Region.

EIPICO has the First Biotechnology and Genetic Engineering Research Center in Egypt manufacturing biopharmaceutical products.

EIPICO manufactures more than 400 Pharmaceutical Products covering 24 Therapeutic Groups.

EIPICO holds License Agreements with a group of international pharmaceutical companies to produce their products locally.

EIPICO is currently the Largest Provider of Antibiotics, Lyophilized Products and Spansule Capsules to the Egyptian market.



EIPICO ... Yes We Care

EIPICO is ranked Number 1 in the Egyptian Ophthalmic Market, by units.

EIPICO is ranked Number 1 in Egyptian Exports of Pharmaceutical Products Export, capturing 21% of Egypt's Total Exports of Pharmaceutical Products.. It currently exports to More than 65 Countries around the world, including Arab, African, Asian, European, Latin American and CIS (Commonwealth of Independent States) countries.

In 2014, the World Health Organization accredited EIPICO, as an approved supplier of one type of sterile antibiotic products, being the First company in Egypt and in the Middle East Region.



EIPICO ... Yes We Care

ISO 9001



ISO 14001



EIPICO ... Yes We Care

ISO 45001

bsi.  

Certificate of Registration

OCCUPATIONAL HEALTH & SAFETY MANAGEMENT SYSTEM - ISO 45001:2018

This is to certify that:

Egyptian International
Pharmaceutical Industries Co Ltd
Ind Area B1
Tenth Of Ramadan City
Egypt

Holds Certificate No: **OHS 580555**
and operates an Occupational Health and Safety Management System which complies with the requirements of
ISO 45001:2018 for the following scope:

The design, development, manufacturing, marketing and supply of pharmaceutical products.
Previously registered to OHSAS 18001:2007 since 18/01/2012

For and on behalf of BSI: 
Andrew Launn, EMEA Systems Certification Director

Original Registration Date: 2020-11-16 Effective Date: 2020-11-16
Latest Revision Date: 2020-11-16 Expiry Date: 2024-02-26

  Page: 1 of 2

...making excellence a habit.™

This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract.
An electronic certificate can be authenticated online.
Printed copies can be validated at www.bsigroup.com/ClientDirectory
Information and Contact: BSI, Kitemark Court, Davy Avenue, Knowlhill, Milton Keynes MK5 8PP, UK. Tel: +44 345 080 9000
BSI Assurance UK Limited, registered in England under number 2805371 at 389 Chiswick High Road, London W4 4AL, UK.

BS OHSAS 18001

bsi.  

Certificate of Registration

OCCUPATIONAL HEALTH AND SAFETY MANAGEMENT SYSTEM - BS OHSAS
18001:2007

This is to certify that:

Egyptian International
Pharmaceutical Industries Co Ltd
Ind Area B1
Tenth Of Ramadan City
Egypt

Holds Certificate No: **OHS 580555**
and operates an Occupational Health and Safety Management System which complies with the requirements of BS
OHSAS 18001:2007 for the following scope:

The design, development, manufacturing, marketing and supply of pharmaceutical products.
Previous certificate expired on 26/2/2018
Re-certification assessment ended on 21/9/2017

For and on behalf of BSI: 
Andrew Launn, EMEA Systems Certification Director

Original Registration Date: 2012-01-18 Effective Date: 2018-03-20
Latest Revision Date: 2018-04-24 Expiry Date: 2021-02-26

  Page: 1 of 2

...making excellence a habit.™



EIPICO ... Yes We Care

The Manufacturing of Medical Devices (Eye Drops) Certificate ISO 13485

Certificate of Registration

This is to Certify that
Medical Device Quality Management System of

EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIAL COMPANY [EIPICO]

**10TH OF RAMADAN CITY- INDUSTRIAL AREA
B1 - P.O. BOX. 149 TENTH-EGYPT.**

has been assessed and found to conform to the requirements of
ISO 13485:2016
for the following scope :

MANUFACTURING OF MEDICAL DEVICES [EYE DROPS].

Certificate No : **18IMCJ03** UIC : **MSCB-119-64402**
Initial Registration Date : 03.10.2018 Issuance Date : 08.10.2018
Date of Expiry* : 02.10.2021
1st Surve. Due : 03.09.2019 2nd Surve. Due : 03.09.2020

Director

AQC MIDDLE EAST FZE.
E1-1401 E Amber Gem Tower, Sheikh Khalifa Bin Zayed Road, 2, Ajman, UAE. e-mail : info@aqcworld.com
*Validity of the Certificate is subject to successful completion of surveillance audits on or before the date. (In case surveillance audit is not allowed to be conducted, this certificate shall be suspended/withdrawn)
Certificate Verification: Please check the validity of certificate at any time by visiting our website www.aqcworld.com or www.aqcworld.com/verify
*Certificate is the property of AQC Middle East FZE and shall be returned immediately upon demand.

the Medicines and Healthcare Products Regulatory Agency Certificate of U.K. (MHRA Certificate)

Safeguarding public health

MHRA

RESTRICTED – COMMERCIAL

Dr Shafiq Choudhary
Intrapham Laboratories Ltd.
Kidwells Park House
Kidwells Park Drive
Maidenhead
Berkshire
SL6 8AQ

Date 01 February 2011

Case No: Insp GMP 20098/13049-0004

Dear Dr Choudhary,

MEDICINES ACT 1968
INSPECTION OF OVERSEAS MANUFACTURING AND CONTROL SITES FOR
PRODUCT LICENCE NUMBERS PL 17509/0009 (Feospan Spansule Capsules) &
PL 17509/0010 (Fefol Spansule Capsules)

I refer to the inspection carried out at EIPICO, Cairo, Egypt on 16 to 19 August 2010.

Our inspection findings and subsequent correspondence allow us to recommend to the Licensing Authority continued support for the naming of this site on the product licences detailed above.

Any matters arising from this inspection will be reviewed at the next inspection.

Yours sincerely

Mark Birse
Mark Birse
Operations Manager GMP
E-mail: Mark.Birse@mhra.gsi.gov.uk

Medicines and Healthcare products Regulatory Agency
121 Buckingham Palace Road London SW1W 9SZ
T 0203 080 6000 www.mhra.gov.uk

An executive agency of the Department of Health

SFDA Certificate

الهيئة العامة للغذاء والدواء
Saudi Food & Drug Authority
رقم الصادر : 21/84
تاريخ الصادر : 1437 / 06 / 28
سوق المرفق : لا يوجد
الإدارة : المكتب الفني لشركة إيبكو

المملكة العربية السعودية
الهيئة العامة للغذاء والدواء
(٢٥٥)
قطاع الدواء

صورة مع التحية للمدير التنفيذي لشركة خالد بن سعد الدولية
المكرم مدير المكتب العلمي لشركة إيبكو
السلام عليكم ورحمة الله وبركاته

بناءً على قرار لجنة تسجيل شركات ومصانع الأدوية ومنتجاتها رقم ٣٧/سfdل/٨٨/١٦ في جلستها رقم ٨٨/سfdل/١٤/٢٢ وتاريخ ١٤٣٧/٠٤/٢٢ هـ المعتمدة من قبل معالي الرئيس التنفيذي، عليه تفديكم بالموافقة على تجديد تسجيل الشركة أدناه لمدة خمس سنوات.

اسم الشركة	رقم التسجيل	تاريخ التجديد	اسم الوكيل
EGYPTIAN INTERNATIONAL PHARMACEUTICAL COMPANY (EIPICO)	١٩٨٧/٢٠١	١٤٣٧/٠٤/٢٢ هـ الموافق ٢٠١٦/٠٧/٠٢ م	شركة خالد بن سعد الدولية المحدودة
اسم الشركة	جنتيتها	عنوانها	رقم التسجيل
مصر	10th of Ramadan City, Industrial Area B1- EGYPT	١٩٨٧/٢٠١	١٩٨٧/٢٠١
اسم الشركة	جنتيتها	عنوانها	رقم التسجيل
مصر	10th of Ramadan City, Industrial Area B1- EGYPT	١٩٨٧/٢٠١	١٩٨٧/٢٠١
اسم الشركة	جنتيتها	عنوانها	رقم التسجيل
مصر	10th of Ramadan City, Industrial Area B1- EGYPT	١٩٨٧/٢٠١	١٩٨٧/٢٠١

الخطوط المسجلة

وفقاً للشروط التالية:

١- للهيئة الحق في إلغاء تسجيل الشركة في الحالات التالية:

أ. إذا لم يتقدم بطلب تسجيل أي من مستحضراتها خلال سنة من إبلاغ الوكيل.

ب. إذا ثبت التزوير أو التلاعب في شهاداتها.

٢٢٢٢ الطريق الدائري الشمالي - حي النخل - الرياض ١٣٣١٢ - ١٣٣٨٨ - المملكة العربية السعودية - هاتف: ٩٦٦ ١١ ٢٠٣٨٢٢٢ - فاكس: ٩٦٦ ١١ ٢٠٣٨٢٢٢
3292 Northern Ring Rd. - Al Nafal District - Riyadh 13312-6288 - Kingdom of Saudi Arabia - Tel: +966 11 2038222 - Fax: +966 11 2057635
www.sfd.gov.sa



EIPICO ... Yes We Care

Gulf Central Committee for Drug Registration (GCC Certificate)

EXECUTIVE BOARD
OF THE
Health Ministers' Council
FOR
Cooperation Council States

المكتب التنفيذي
لوزراء الصحة
للدول مجلس التعاون

شهادة تسجيل موقع تصنيع
REGISTRATION CERTIFICATE OF MANUFACTURING SITE

المكتب التنفيذي لوزراء الصحة لدول مجلس التعاون / تسجيل / إعادة تسجيل
موقع التصنيع التالي وذلك وفقاً لاجتماع اللجنة الخليجية المركزية للتسجيل الدوائي

The Executive Board of the Health Ministers' Council for Cooperation Council States approved the ☐ Registration / ☒ Re-registration of the following Manufacturing Site according to Gulf Central Registration Committee meeting

No.: 74 Date: 13/12/2015

رقم مواقع التصنيع والتاريخ 13/12/2015

Manufacturing Site Name:	Egyptian International Pharmaceutical Ind. Co. (Eipico)	اسم موقع التصنيع
Address:	10th of Ramadan City, Industrial area B1, Cairo, Egypt.	العنوان
Production line(s):	- See Annex 1.	خطوط الإنتاج
Registration No. & Date:	GRC/112/03 20/12/2003	تاريخ ورقم التسجيل
Date of Issue:	19/12/2015	تاريخ إصدار الشهادة
Remarks:		ملاحظات

الدبر العام
Director-General

أ.د. توفيق بن أحمد خوجة
Prof. Tawfik A.M. Khoja

رئيس قسم التسجيل
Head of Registration Department

ص / محمد بن حمد الحيدري
Ph. Mohammed H. Al-Haidari

هذه الشهادة صالحة لمدة خمس سنوات من تاريخ إصدارها
في تمديد / كخط في قيد الشهادة ينبغي تسجيلها

This Certificate is Valid for Five years from date of issue
Any amendment or scraping off in the certificate will lead to its cancellation.

Marketing Authorization Certificate of Romania

Republika e Kosovës - Republika Kosova - Republic of Kosovo
Qeveria - Vlada - Government
Ministria e Shëndetësisë - Ministarstvo Zdravstva - Ministry of Health

Agencia e Kosovës për Produkte dhe Pajisje Medicinale
Kosovo Medicines Agency
Kosovska Agencija za Lekove i Medicinska Sredstva

Marketing Authorisation Certificate

MA No: MA-4531/10/06/2016
Date: 10/06/2016

Based on, the provisions of the Law No.04/L-990 On "Medicinal Products and Medical Devices" and, Administrative Instruction (Health) No. 3/2015 issues to applicant:

E.I.P.I. CO MED S.R.L - Romania

For medicinal product

Product Trade Name: TIMOLOL
INN: Timolol Maleate
Manufacturer: EIPICO- Egypt
Dosage Form & Strength: Ophthalmic solution, 5.0 mg
Pack Size: Opaque white plastic bottle (of 5ml)
ATC Code: S 01 ED 01

Expiry date: 10/06/2021

This medicinal product, based on the approved, application documentation, Summary of Product Characteristics and Patient Information Leaflet, submitted by applicant is permitted to be placed in Kosovo for a period of 5 years. The Holder of the Marketing Authorisation, warrants that the documentation and samples concerning the medicinal product are valid at the day issuance of this Marketing Authorisation Certificate and shall be valid for the duration of this Certificate, unless an application for a variation is made and approved by issuing authority.

Copy to:

- The applicant
- The EMA archive

Pharm-D Jeton Shala
Chief Executive Officer of Kosovo
Medicines Agency

Romania Certificate

MINISTRY OF HEALTH
NATIONAL AGENCY FOR MEDICINES
AND MEDICAL DEVICES
48, Av. Sanatescu St, sector 1, 011478 Bucharest
Tel: +4021-317.11.00
Fax: +4021-316.34.97
www.anm.ro

Certificat Nr./Certificate No: 020/2019/RO

CERTIFICAT PRIVIND CONFORMITATEA CU BUNA PRACTICĂ DE FABRICAȚIE
CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER
Partea I/Part I

Emis în urma unei inspecții în acord cu art. 111(5) al Directivei 2001/83/EC/Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC.

Autoritatea competentă AGENȚIA NAȚIONALĂ A MEDICAMENTULUI ȘI A DISPOZITIVELOR MEDICALE din ROMANIA confirmă următoarele: The competent authority NATIONAL AGENCY FOR MEDICINES AND MEDICAL DEVICES from ROMANIA confirms the following:

Fabricantul/The manufacturer: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES CO.

Adresa locului de fabricație/Site address: 10th of Ramadan City, Industrial Area B1, P.O. BOX 149 - 10th, Egypt

A fost inspectat în legătură cu autorizația (autorizațiile) de punere pe piață care se referă la fabricanți situați în afara Spațiului Economic European în acord cu art. 8(2)/33(2)/19(3)/44(3) al Regulamentului (EC) 726/2004 sau cu art. 111(4) al Directivei 2001/83/CE transpusă în legislația națională prin art. 857 alin. 4 din Legea nr. 95/2006 privind reforma în domeniul sănătății, republicată, Titlul XVIII, Medicamentul/Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 8(2)/33(2)/19(3)/44(3) of Regulation (EC) 726/2004 or Art. 111(4) of Directive 2001/83/EC transposed in the following national legislation: art. 857 (4) from Law no. 95/2006 regarding the reform in the field of health, republished, Title XVIII, Medicinal product

Din informațiile acumulate în timpul inspecției la acest fabricant, ultima fiind efectuată în 2018/12/11, se apreciază că acesta respectă cerințele de Bună Practică de Fabricație la care se face referire în Principiile și ghidurile pentru Bună Practică de Fabricație stabilite în Directiva 2003/94/CE/From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2018/12/11 it is considered that it complies with the Good Manufacturing Practice requirements referred to in The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC.

Acest certificat reflectă statutul locului de fabricație la data inspecției menționată mai sus și nu mai poate fi luat în considerare dacă de la data acestei inspecții au trecut mai mult de trei ani. Accusată perioada de valabilitate poate fi redusă folosind principiul de management al riscului în activitatea de reglementare, printre-o remarcă menționată la rubrica „Restricții sau observații care să clarifice”. Acest certificat este valid numai dacă are toate paginile incluse precum și ambele Părți (1 și 2). Autenticitatea acestui certificat poate fi verificată în baza de date EudraGMP. Dacă nu este inclus în această bază de date, vă rugăm să contactați autoritatea emitentă. This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts I and 2. The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

28/03/2019

Numele, titlul și semnătura persoanei autorizate din Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România
Name and signature of the authorised person of the National Agency for Medicines and Medical Devices from Romania
Tel.: 0040 21 317 11 02 Fax: 0040 21 316 34 97
Marius Daniel Sîrb, Președinte
Semnătura:
Stampila:

1/3



EIPICO ... Yes We Care

Manufacturing Site Registration Certificate of U.A.E.,

UNITED ARAB EMIRATES
MINISTRY OF HEALTH

الإمارات العربية المتحدة
وزارة الصحة

MANUFACTURING SITE REGISTRATION CERTIFICATE

It is certified that the following Manufacturing Site has been registered in the UAE Ministry of Health, in accordance with the Article 65 of the Federal Law No. 3 of 1984.

Certificate #	03869C02	First Reg. Date	27-July-2009
Registration #	3609	Reg. Expiry Date	08-February-2020
Committee Meeting No.	10940	Meeting Date	08-February-2015
Payment Receipt No.	0103482710141012	Payment Date	27-October-2014
Manufacturing Site Name	EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES CO. (E.I.P.I.CO)		
Address	Tenth of Ramadan City, Po Box : 149, EGYPT, Tenth of Ramadan City		

Activities Registered for
Manufacture of dosage forms, Packaging & Labelling, Storage & Handling, Laboratory Testing, Batch releaser (certification), Secondary packaging

Hazard Line(s) of Production Registered for

Beta-lactam antibiotics:
(1) Sterile Products-Aseptically prepared (Dosage Forms)
Lyophilisates, Small Volume Liquids
(1) Sterile Products-Terminally Sterilized (Dosage Forms)
Lyophilisates, Small Volume Liquids
(2) Non-Sterile Products-Non Sterile Products (Dosage Forms)
Capsules, hard shell, Liquids for internal use, Tablets

Hormones
(1) Sterile Products-Aseptically prepared (Dosage Forms)
Small Volume Liquids
(1) Sterile Products-Terminally Sterilized (Dosage Forms)
Small Volume Liquids

Non Hazard Line(s) of Production Registered for

(1) Sterile Products-Aseptically prepared (Dosage Forms)
Lyophilisates, Small Volume Liquids, Powder, Small Volume Liquids (Eye Drops), Semi-Solids (Ointment), Semi-Solids (Cream)
(1) Sterile Products-Terminally Sterilized (Dosage Forms)
Small Volume Liquids
(2) Non-Sterile Products-Non Sterile Products (Dosage Forms)
Capsules, hard shell, Capsules, soft shell, Liquids for internal use, Liquids for external use, Other Solid dosage forms, Semi-Solids, Suppositories / pessaries, Tablets, Effervescent Tablets, Effervescent Powder, Powders

Issued on: 2/8/2015

www.government.ae

تلفون: +971 2 633 8888 • فاكس: +971 2 633 8888 • بريد إلكتروني: info@eipico.ae • الإمارات العربية المتحدة
تلفون: +971 2 633 8888 • فاكس: +971 2 633 8888 • بريد إلكتروني: info@eipico.ae • الإمارات العربية المتحدة
تلفون: +971 2 633 8888 • فاكس: +971 2 633 8888 • بريد إلكتروني: info@eipico.ae • الإمارات العربية المتحدة

Registration Certificate of a Foreign Pharmaceutical Plant of Sudan

The Republic of Sudan
Federal Ministry of Health
National Medicines & Poisons Board
Secretariat General

وزارة الصحة الاتحادية
المجلس القومي للأدوية والسُموم
الأمانة العامة

REGISTRATION CERTIFICATE OF A FOREIGN PHARMACEUTICAL PLANT

بهذا نشهد أن المصنع أدناه مسجل لدينا وذلك وفق البيانات المدرجة

We hereby certify that the following pharmaceutical manufacturing plant has been approved for renewal of registration according to the information given below.

Date:	22/01/2017	التاريخ:
Manufacturer's Name:	Egyptian International Pharmaceutical Industries Co	اسم المصنع:
Origin:	Egypt	المصدر:
Address:	10 th of Ramadan City – Industrial Area, Egypt	العنوان:

Production lines:

A. General Products:

1. Non-Sterile Products:

1.1. Solid dosage form:

1.1.1. Tablets. 1.1.2. Capsules (Hard & Soft)

1.2. Liquid dosage forms:

1.2.1. Suspensions. 1.2.2. Syrups.

1.2.3. Oral Drops.

1.3. Semi Solid dosage forms:

1.3.1. Cream. 1.3.2. Ointment.

1.3.3. Gel. 1.3.4. Suppositories

B. β - Lactam Products:

1. Non-Sterile Products:

1.1. Tablets. 1.2. Powder for oral use.

Local Agent's Name: Kambal International Company
8th Floor Alfatih Bldg., Ali A/ Latif Street
Khartoum - Sudan
Address: Tel: 779337, 775586, 785939 Fax: 775887
الموكل المحلي:

Committee Meeting No.	01/2017	رقم اجتماع اللجنة	Date of Registration	19/01/2017	تاريخ تجديد الإجازة
-----------------------	---------	-------------------	----------------------	------------	---------------------

This certificate is valid only for a period of five years from the renewal of registration date, unless suspended or revoked.

هذا الشهادة صالحة لمدة 5 سنوات من تاريخ تجديد الإجازة ما لم تعلّق أو تلغى

د. زين العابدين عباس محمد المحفل
الرئيس العام للمجلس القومي للأدوية والسُموم

NAFDAC Certificate

NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL

NAFDAC CORPORATE HQ
Plot 2032, Oshogbo Obaanjo Way,
Wuse Zone 7, Abuja.
Tel: +234-9-6718008
E-mail: nafdac@nafdac.gov.ng

LAGOS LIAISON OFFICE
Central Laboratory
No. 9/5 Oshodi Apapa Expressway
Lagos State.
Tel: +234-1-4730643
E-mail: nafdac@nafdac.gov.ng

DRUG EVALUATION AND RESEARCH DIRECTORATE, ISOLO, LAGOS
NAFDAC/DER/HQ/VOL2/18
10th December, 2015

Your Ref: _____ Our Ref: _____ Date: _____

The Managing Director,
Egyptian International Pharmaceutical Industries Company,
10th of Ramadan city,
Industrial Zone B1, P.o.box 149,
Cairo, Egypt.

GOOD MANUFACTURING PRACTICE (GMP)

This is to certify that the GMP assessment of your Factory by inspectors from National Agency for Food and Drug Administration and Control (NAFDAC) Nigeria on 31st October – 1st November, 2015 was **Satisfactory**.

The product lines inspected were:

- Non – Beta Lactam
- Beta Lactam
- Semi- Solids
- Liquid Dosage Forms
- Sterile Products
- Oral Solid Dosage

You are to ensure that this standard is consistently maintained.

Regards
Mrs. Titilope O. Owolabi
For: Director-General (NAFDAC).



EIPICO ... Yes We Care



World Health
Organization

World Health Organization Pre-qualification



World Health
Organization

20, AVENUE APPA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Tel. direct: +41 22 791 40 29
Fax direct: +41 22 791 47 30
E-mail: prequalification@who.int

In reply please
refer to: P5-447-3/IT/AGM/1

Your reference:

Dr Omar El Ahmady
R&D and Quality sector Director
Egyptian International Pharmaceutical
Industries Co. S.A.E.
Tenth of Ramadan City
Industrial Area B1
P.O. Box 149 Tenth
Egypte

22 August 2013

Dear Dr El Ahmady,

WHO Prequalification of Medicines Programme Closing of Inspection

Thank you for your letter and the corrective actions to the observations listed in the inspection report following the inspection as detailed below:

Name: Egyptian International Pharmaceutical Industries Co. S.A.E.
Address: Tenth of Ramadan City, Industrial Area B1, P.O. Box 149 Tenth, Egypt
Date: 4-7 March 2013

The actions taken or proposed to be taken in relation to the observations listed in the WHO inspection report have been reviewed by the inspectors. In general, they are considered acceptable and will be verified during future inspections. **The site is considered to be operating in compliance with WHO Good Manufacturing Practices (GMP).**

Please do not hesitate to send an email to prequalification@who.int should you require any further information regarding the closure of this inspection.

Yours sincerely,

Dr Deis Mubangizi
Acting Head of Inspections
Prequalification of Medicines Programme
Quality Assurance & Safety: Medicines

منظمة الصحة العالمية • 世界卫生组织

Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud



World Health
Organization

20, AVENUE APPA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Tel. direct: +41 22 791 3615
Fax direct: +41 22 791 4730
E-mail: prequalification@who.int

In reply please
refer to: P5-447-3/XC/1

Your reference:

Dr. Magda Ibrahim
Global Quality General Manager,
Egyptian International Pharmaceutical Industries
Company (EIPICO), 10th of Ramadan City
Industrial Area B1
P.O. Box 149 - 10th
Egypte

20 December 2019

Dear Dr Ibrahim,

WHO Prequalification Team - Inspection Services Closing of Inspection: Egyptian International Pharmaceutical Industries Company (EIPICO)

I refer to the inspection that was performed by Ms. Xingyu Chen and Mr. Mr. Ian Richard Thrussell the details of which are outlined below:

Site name: Egyptian International Pharmaceutical Industries Company (EIPICO)
Block: Cephalosporin Block (Perry II, IMA I)
Address: Tenth of Ramadan City, Industrial Area B1, Egypt
Date: 6 - 9 May 2019

Thank you for your letter dated 24 November 2019 and the corrective actions to the deficiencies listed in the inspection report. The actions taken, or proposed to be taken, to correct the deficiencies have been reviewed by the Prequalification Inspection Group.

In general, they are acceptable. Therefore, considering these responses, as well as the findings of the inspection, the Prequalification Inspection Group has recommended that the site can be considered to be compliant with the standards of Good Manufacturing Practices (GMP) published by the World Health Organization (WHO) for the scope activities listed below:

- Manufacture and packaging of aseptically filled powder for solution for injection in the Cephalosporin Block

منظمة الصحة العالمية • 世界卫生组织

Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud

Dr Ibrahim, Cairo
P5-447-3/XC/1

20 December 2019
Page 2

The inspection findings and your response allow Prequalification Inspection Group to recommend to the Prequalification Assessment Group that the site inspected may continue to be named as a manufacturing site in the dossier for the following products:

PQT Number	Product	Strength	Dosage Form	Applicant
HA479	Ceftriaxone Sodium	500mg	Powder for solution for injection	EIPICO
HA480	Ceftriaxone Sodium	1g	Powder for solution for injection	EIPICO

Please do not hesitate to send an email to prequalification@who.int should you require any further information regarding the closing of this inspection.

Yours sincerely,

Dr Joey Gwows
Group Lead, Inspection Services
Prequalification Team
Regulation of Medicines and other Health Technologies

منظمة الصحة العالمية • 世界卫生组织

Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud



Company Profile | 2020

EIPICO has been accredited ISO Certificates besides Certificates from European, African, and Asian Health Authorities.

EIPICO... Egypt's Leading Pharmaceutical Company



Factory 1



Factory 2

Production

EIPICO Production Sector is the beating heart of the company's business. Due to its capability and high performance, the production sector has helped **EIPICO** to attain its remarkable position in the market, not only in **Egypt** but also in the **Middle East and North Africa (MENA) Region**.

During the last decade, a great upgrading and modifications took place in order to have the best machines and equipment characterized by high speed, and full automation including robotic systems, in addition to conversion of all production departments to smart building units with total control of Temperature, Humidity and Differential pressure between different rooms.

The production system in **EIPICO**, depends on Total Quality Control with the application of Zero Defect System.



EIPICO Production Capacity / Year

EIPICO is the Leading Egyptian Pharmaceutical Company, in Production, by Units.


EIPICO is the **Major Provider** of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.




2,061,582,500
Tablets



409,650,000
Capsules



27,837,500
Sterile Eye Drops



354,357,320
Injectable Ampoules
and Vials




18,062,500
Ointment and Cream
Tubes



137,600,000
Effervescent Sachets



79,750,000
Syrup and Suspension
Bottles



36,125,000
Suppositories

Facilities

Factory 1

- **Factory 1** was built in 1980 and renewed using state-of-the-art construction system and materials in compliance with International **Society for Pharmaceutical Engineering (ISPE)** regulations assuring clean environment for all production rooms to provide maximum protection for both products and personnel.
- The site contains several departments for manufacturing of many Dosage Forms.
- It includes: the Largest and Most Advanced **Sterile Area** in Egypt and in the MENA region, separated areas for Sterile Cephalosporin Antibiotics, Sterile Penicillin Antibiotics and Non Sterile (Oral) Antibiotics to prevent cross-contamination with up to date containment systems.
- Other activities performed in the site include: warehousing, engineering and other administrative functions.

Facilities

Factory 1



Sterile Ampoules and Vials
Department



Sterile Eye Drops Department



Sterile Cephalosporin Antibiotics
Powder Area Department (IMA I)



Sterile Cephalosporin Antibiotics
Powder Area Department (Perry II)



Sterile Penicillin Antibiotics Powder
Area (IMA II) Department



Sterile Penicillin Antibiotics Powder
Area (Perry I) Department

Facilities

Factory 1



Oral Antibiotics Department



Solid Dosage Forms (Hard Gelatin Capsules and Tablets) Department



Soft Gelatin Capsules Department



Semi Solid Department



Liquids Department

Facilities

Factory 2

- **Factory 2** was launched in 2013 to fulfill the ever-growing demand of both national and international markets.
- The production facilities have been designed to cope with the latest **cGMP** and **WHO** regulations.
- The site's main production building contains **6** Manufacturing Departments which are: Sterile Hormones and Corticosteroids, Sterile Eye Drops, Tablets, Effervescent granules, Syrup and Suspension and Semi solid Departments.

Facilities

Factory 2



Sterile Hormones Department



Sterile Eye Drops Department



Tablets Department



Effervescent Granules
Department




Syrup and Suspension
Department



Semi Solid Department

Sales and Production

EGP Millions



Therapeutic Lines



PENICILLINS

- FLUMOX
- E-MOXCLAV
- NOVACTAM
- E-MOX
- EPICOCILLIN

CEPHALOSPORINS

- CEFOTAX
- EPICEPHIN
- CEFIDIME
- CEFOZON
- CEPHRADINE

QUINOLONES

- CIPROCIN
- EPINOR
- EPICOFLOCIN

ANTIFUNGALS

- TREFLUCAN
- NYSTATIN

MACROLIDES

- EPIZITHRO

ANTI-VIRALS

- EPIMIRAFLU
- EPIFLUVER
- EPISOVIR

AMINOGLYCOSIDES

- EPIGENT

TETRACYCLINES

- DOXYDOX

ANALGESICS & ANTI-RHEUMATICS

- CETAL
- EPIFENAC
- EPICOTIL
- VASTAFLAM

CARDIOVASCULAR

- ATOR
- EPIROVASTIN
- CAPOTRIL
- LOSAZIDE
- RAMPECARDIN
- CO-VASOTEC
- VASOTEC
- EPILAT/RETARD
- REGCOR
- DILTIAZEM
- ATENO/C
- EPIDOPA
- EPITENS
- THROMBO
- ETHANOLAMINE OLEATE

ALIMENTARY & METABOLISM

- REPAGLINIDE
- GLICLA MR
- PICOLAX
- LACTULOSE
- COLOSPASMIN
- GASTROMOTIL
- MUCOGEL
- EPICOGEL
- GASTROFAIT
- EPIRAZOLE
- EPINOS

SYSTEMIC CORTICOSTEROIDS

- EPIDRONE
- DEXAMETHASONE
- EPIRELEFAN
- EPIZOLONE-DEPOT
- EPICOPRED

UROLOGICALS

- SILDEN
- EPIMAG
- OXYBIN
- DOSIN

COUGH & COLD PREPARATIONS

- SELGON
- BRONCHOPHANE
- NEO-BRONCHOPHANE
- CETAL COLD & FLU
- CONTA FLU
- CETAL SINUS

DERMATOLOGICALS

- BETADERM
- CAMISAN
- NYSTAFORM
- ALLERGEX
- MINOX

ANTIPROTOZOALS & ANTHELMINTICS & INTESTINAL ANTI-INFECTIVES

- ALZENTAL
- SECNIDAZOLE
- FURAZOL
- EPIQUANTEL
- DISTOCIDE
- KAPECT
- KAPECT COMPOUND
- NIFUROX

VITAMINS & TONICS & ANTIANAEMICS

- EPICOZYM
- MINERAVIT
- CEVITIL
- VITAZINC
- EPINOSINE B
- FERRO FOL
- FERROFOLVIT-Z
- FOLIC ACID
- EPOFORM
- VITONA PLUS

NERVOUS SYSTEM

- **NORMOLEPSY**
- **LEVEPSY**
- **EPIMAZEPINE**
- **OLAZINE**
- **RISDAL**
- **EPISTIGMIN**
- **HISTOTEC**
- **FLUTIN**

SYSTEMIC HORMONES

- **EPIFASI**
- **EPIGONAL**
- **PROGESING**

HOSPITAL SOLUTIONS

- **POTASSIUM CHLORIDE**
- **CALCIUM CHLORIDE**
- **MAGNESIUM SULPHATE**

ANAESTHETICS

- **THIOPENTAL**

SYSTEMIC BLOOD COAGULANT

- **EPIKAVIT**
- **PROTAM**

ANTI HISTAMINICS

- **EPIRIZINE**
- **ALLERGEX**
- **ALLERGEX CAFFEINE**
- **FEXOSTADINE**

ANTI-ASTHMA

- **EIPICOPHYLLINE**
- **EIPICOPHYLLINE PHENOBARBITONE**

EYE & EAR PREPARATIONS

- DEXATROL
- TOBRIN
- DEXATOBRIN
- BENOX
- EPIFENAC
- CIPROCIN
- NEO POL
- NORMO-TEARS
- TIMOLOL
- OLOHISTINE
- NEO MYXIDIN

EYE & EAR PREPARATIONS

- NEO MYXIDIN
- EPIDEXONE
- EPISOPT
- EPICROM
- EPIPHENICOL
- EPITAXOL
- XALATREX
- OPTIGENT

NASAL DECONGESTANT

- NOSTAMINE

STOMATOLOGICALS

- EPIDENT

ANTI-GOUT

- NO URIC




Antibiotics

Antivirals



Osetamivir
75 mg




Remdesivir
100 mg



Favipiravir
200 mg



Azithromycin
500 mg



Ceftriaxone
1 gm

Analgesic & Antipyretic



Paracetamol
500 mg

Systemic Corticosteroids



Prednisolone
5 mg




Hydrocortisone sodium succinate
100 mg



Dexamethasone sodium phosphate
8 mg / 2 ml

Multivitamins



Iron with Folic acid, Vitamins and Zinc



Vitamin C
1 gm

Cough Preparations



Guaifenesin, Diphenhydramine hydrochloride, Oxeladin citrate



Guaifenesin
400 mg



“Through generating innovative entrepreneurial ideas, meticulous planning, and with the support of hardworking, enthusiastic, diligent, high-performance teams, working in tandem, and committed to their duties, we shall continue to fulfill our mission of expanding our production of high quality products, to satisfy the needs of the medical community.”

A. Kelani



EIPICO implements a Track and Trace Program based on GS1 DataMatrix, the most widely used identification system worldwide, to ensure patient safety and enhance supply chain efficiency.

The problem of counterfeit drugs is not a new one, but it is a growing issue and one that cannot be ignored. It has become an increasing global threat over the last few decades.

EIPICO, as a leading pharmaceutical manufacturer, was of the first to use GS1 DataMatrix which is a system in which the supplier can mark items in the expectation that all trading partners will be able to read and correctly interpret the data encoded.

This DataMatrix is a (2D or two-dimensional) barcode which may be printed as a square or rectangular symbol made up of individual dots or squares.



GS1 DataMatrix encodes information such as, but not limited to: Global Trade Item Number (GTIN), a globally unique identification number for medical products, Expiration Date, Batch Number and Serial Number.

GS1 defines trade items as products or services that are priced, ordered or invoiced at any point in the supply chain.

GTIN once assigned to a trade item, it provides a common language for all of its entities and trading partners worldwide to uniquely identify the item and easily communicate information about the item.

Track & Trace Program is the current **EIPICO's** Project with the mission that all packaging lines will be provided by DataMatrix Systems.

This is being worked on nowadays and will be accomplished by **2020**.



Biotechnology Center

EIPICO has the First Biotechnology and Genetic Engineering Research Center in Egypt.

The Biotechnology Center was established in 2000 with the mission of being the First Facility in Egypt capable of producing Biopharmaceutical Drug Substances and Drug Products by applying and implementing all the required state-of-the-art techniques:

USP: Tissue Culture, Fermentation.

DSP: Affinity, IEX, Size Exclusion, TFF, Ultra-Filtration

Analysis: SDS-PAGE Electrophoresis, Isoelectric Focusing, Western Blot, Peptide mapping, RT-PCR, BioAssay, ELISA.



The Biotechnology Center now produces rh- Erythropoietin Hormone which is marketed under the name of EPOFORM 2000 IU/ml and EPOFORM 4000 IU/ml.

Research & Development

We believe in continuous discovery, improvement and creativity; that's why we invest annually in our R&D labs to bring the state-of-the-art equipment for formulation, characterization and analytical activities.

Our R&D team serves in two major trends:

1. The Productive trend which is exhibited in all lab scale trials and scale-up activities of all pharmaceutical dosage forms.
2. The Responsive trend manifested in troubleshooting of production, non-conforming reports and stability problems.

Our R&D team, is the spearhead of our company to maintain a cutting edge performance in nowadays fierce competition and to keep up with the era of global progress and sustainable developments.



Quality Control

We foster a quality control culture based on:

- Highly-qualified/proactive personnel.
- An environment of continuous improvement.
- Robust and standardized laboratory that utilizes the most cutting-edge instrumentation and methodologies to provide the most precise and accurate results, with ALL our testing being done "In-house".



Quality Assurance

Every member in our team has a significant role to play in order to achieve our mission successfully by bringing high quality pharmaceutical products to the Egyptian and International markets.

We are certain that our values are embedded in our culture and our decision making helps us to meet the expectations of the society.

We encourage associates to achievement through organized collaboration. Consequently, our quality members are provided with the right decision making authority giving a guarantee for short decision routes.



Pharmacovigilance

Report... Your Report Counts.

The aim of EIPICO Pharmacovigilance Department is to enhance patient's health and safety in relation to the use of EIPICO products through providing reliable, and balanced information to ensure that the overall benefits of medicines outweigh the risks.

Such aim is fulfilled by collecting Adverse Drug Reaction Reports/Customer Complaints and preparing Pharmacovigilance documents for each of EIPICO marketed products routinely, to assess the medicines Benefit/Risk balance.

Thus, by reporting Adverse Drug Reactions/Complaints witnessed from a drug, we share in the continuous monitoring of the safety, efficacy and quality of the drug beside ensuring that the Benefit/Risk balance is updated in order to reach safer medicinal products and have a positive impact on the public safety/health.



Safety First

Plastic Factory

The main goal of establishing the factory was far beyond achieving any financial gain, but only to maintain the high quality level of EIPICO's Eye Drops assuring the sterility of the medicament all through the production process up to the end user.

This target was not achievable regarding the low quality of the locally-produced eye drops bottles.

Since the beginning and up till now, the factory covered all EIPICO's needs of Eye Drops Dropper Bottles, Sizes: 5, 10, and 15 ml, with a quality level that matches the highest international standards, and was capable of developing its productivity to fulfill future needs.

- EIPICO decided to establish affiliated factories, in the field of industries feeding the pharmaceutical industries, to ensure the constant and sufficient availability of primary packaging materials, and to avoid the problems of import (shipping and foreign currencies).
- In 2005, Egyptian International Ampoules Company - EIACO was established, as an Egyptian investment company for manufacturing medical ampoules, over the area of 25 thousand square meters in the 10th of Ramadan City. EIPICO is the main investor.

EIACO

Egyptian International Ampoules Company

Affiliate
Company

- Current Production:
 - ✓ 120 Million Vials of Type 1 Vial per year.
 - ✓ 33 Million Aluminum Tubes for the filling of Skin and Eye Ointments.
- EIACO is currently the Largest Manufacturer of Primary Packaging Materials in Egypt, managing to completely secure the needs of EIPICO from Ampoules, Vials and Aluminum Tubes, which is a great success in achieving the strategic objective of its establishment.



EIACO has been accredited the ISO 9001/2015 Quality Certificate.

Alliances

EIPICO has production and under license agreements with many multinational companies.

They all trust our quality standards, experience and capabilities.



Lactulose Hek Syrup



Tebonina Forte Tablets



MENARINI

Altiazem Tablets



ANGELINI

Tantum Verde Mouth Wash & Gargle
Tantum Rosa Vaginal Powder
Tantum Cream Forte & Gel



DOLOGIET

Ibutop Gel
Balkis Drops



ICN Pharmaceuticals, Inc.

Librax Tablets



Norgesic Tablets
Norflex Tablets & Ampoules

EXPORT

We Think Globally



Commitment

EIPICO strengthened global access through partnership and collaboration with international health ministries in tender-based institutional business



Strategy

EIPICO is committed to reach global patients through partnership with local pharmaceutical importers and distributors.



Coverage

EIPICO serves global patients in majority essential therapeutic classes with about 1300 different product files registered worldwide.




Capacity

EIPICO exports about 25% of it's production capacity.

EXPORT

Timeline Progress

We Think Globally



EXPORT

We Think Globally

EIPICO captures

21%

of Egypt's Total Exports
of Pharmaceutical
Products, by value.
(2019)



in Egyptian Exports of Pharmaceutical Products.

“

EIPICO strongly believes in access to high quality affordable priced medicines is a basic human right and we are committed to our vision through.

EXPORT

We Think Globally

EIPICO exports cover

65

countries

in the Middle East, Africa,
Europe, Far East and
Latin America

EIPICO expansion plan targets
15 more countries
by 2022.

Middle East

- Saudi Arabia
- United Arab Emirates
- Kuwait
- Oman
- Bahrain
- Iraq
- Yemen
- Jordan
- Lebanon
- Libya
- Algeria
- Palastine
- Syria
- Qatar
- Morocco*

C.I.S.

- Russia
- Ukraine
- Belarus
- Moldova
- Kazakhstan
- Azerbaijan
- Uzbekistan
- Kyrgyzstan
- Tajikistan
- Turkmenistan
- Georgia
- Mangolia

Europe

- England
- Romania
- Netherlands*
- Albania
- Kosovo*
- Malta

Latin America


- Jamaica
- Ecuador
- Colombia
- Chile*
- Peru*

Far East

- Vietnam
- Malaysia
- Hong Kong
- Myanmar
- Taiwan
- North Korea
- Philippines*
- Thiland*

Africa

- Sudan
- Ethiopia
- Nigeria
- Somalia
- Kenya
- Ghana
- Tanzania
- Uganda
- South of Sudan
- Cote d'Ivoire
- Eriteria
- Burundi
- Chad
- Benin
- Mali
- Namibia
- Niger
- Gambia
- Guinea
- Mozambique
- Madagascar
- Guinea Equatorial
- Djabouti
- Zambia*
- Togo*
- Congo*
- Burkina*
- Rwanda*
- South Africa*
- Swaziland*
- Cameroon*



The FUTURE...

As a continuation of the company's pioneer role in developing the pharmaceutical industry and providing the necessary high quality medications of suitable prices to the Egyptian citizens, EIPICO is studying the manufacturing of Biosimilars in Egypt, with investments of up to One Billion Egyptian pounds, to produce drugs for the treatment of cancer, as well as, hormones.

Chief Executive Officer



Contact us

Tenth of Ramadan

Address: EIPICO, Tenth of Ramadan City - 1st Industrial Zone B1, Egypt.

Telephone: +20554499199. **Fax:** +20554499306.

E-mail: eipico@eipico.com.eg

Commercial Sector E-mail: CommercialSector@eipico.net

Export Sector E-mail: ExportSector@eipico.net

Financial Sector E-mail: FinancialSector@eipico.net

Production Sector E-mail: ProductionSector@eipico.net

Quality Sector E-mail: QualitySector@eipico.net

Yes We Care



Contact us

Branches

Tenth of Ramadan Branch

Tenth of Ramadan City - Industrial Area B 1 (Factory 1 and Factory 2)
0554499199 & Fax: 0554499306
tenth@eipico.net

Cairo & Giza Branches

Address: 3, El Moez Ledin Allah St. from Asmaa Fahmy St., Ard El Golf, Nasr City, Cairo.
Tel: 0224143660 & 0224143550
E-mail: cairo@eipico.net
E-mail: giza@eipico.net

Alexandria Branch

Address: New Mansheya - Muharram Bek - Bridges Highway - The Land of Alexandria Refrigeration Company.
Tel: 03 3600612 - 03 3600615 - 03 3600616 - 03 3600618
E-mail: alex@eipico.net

Mansoura Branch

Address: 13, El-Emam El Ghazali St., Toreil, El Mansoura Second, Dakahlia.
Tel: 050 2328811
E-mail: mansora@eipico.net

Banha Branch

Address: 63, Banha El Zagazig Rd., Qism Banha, Qalyubia.
Tel: 013 3229020 - 01220700406 - 01220700408
E-mail: banha@eipico.net

Tanta Branch

Address: Mohamed Farid St., Off Hassan Radwan St., Tanta.
Tel: 040 / 3325924 - 040 / 3325926
E-mail: tanta@eipico.net

Menia Branch

Address: Stores and Warehouses "Development and Agricultural Credit Bank" - First railway Telah - Minya.
Tel: 086 2351480 - 086 2351474
E-mail: menia@eipico.net

Sohag Branch

Address: Rawafie Al-Kousair, Sohag.
Tel: 093 2334652
E-mail: sohag@eipico.net

Yes We Care

